Vycor Medical, Inc. President David Cantor to Be Interviewed Today on Clear Channel Business Talk Radio DFW1190AM
Mr. Cantor to Be Interviewed Live Today at 2:00 pm CST / 3:00 pm EST on The Traders Network Radio Show by Host Michael Yorba
BOCA RATON, FL–(Jan 23, 2014) – Vycor Medical, Inc. (“Vycor”) (OTCBB:VYCO), a medical device company with a suite of FDA cleared products, announced today that President David Cantor will interviewed live by host Michael Yorba on Clear Channel Business Talk Radio’s The Traders Network.
The interview will air today Thursday, January 23, 2014, at 2:00pm U.S. Central Standard Time / 12:00pm Pacific Standard Time / 3:00pm Eastern Standard Time at DFW1190AM and broadcasted nationally via iHeart Radio.
We encourage all investors, institutional analysts, industry professionals, customers and others who are interested in learning more about Vycor Medical’s NovaVision recent developments to tune in and listen live via Clear Channel’s iHeart Radio stream. Details below.
Live Interview via iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true
Date: January 23, 2014
Time: 2:00pm CST | 12:00pm PST | 3:00pm EST (U.S.)
Network: Clear Channel
Station: DFW 1190AM
Host: Michael Yorba
About Clear Channel: Clear Channel Media and Entertainment’s more than 840 radio stations offer programming nationwide. Individual station brands connect with diverse audiences in local markets across the country. DFW1190AM.com Dallas-Ft. Worth.www.clearchannel.com.
About Michael Yorba: Michael Yorba is the featured host of Clear Channels DFW 1190AM in Dallas-Ft. Worth, TX. For the past six years he has been integrally involved with the media industry in various capacities including building an IPTV Network, developing, producing and hosting a daily one hour talk show called Commodity Classics, and then later The Traders Network, defined as an audience empowered interactive financial program that has been broadcast live on Internet, television and radio. His focus has been on derivative portfolio analysis for individual and corporate clients through the use of futures and futures options, managed funds, and Forex. www.yorbamedia.com.
About Vycor Medical, Inc.
Vycor Medical, Inc. (“Vycor”) is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA-cleared medical solutions that are changing and improving lives every day. The Company operates two wholly owned business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Both technologies have exceptional sales growth potential, address large potential markets, have the requisite regulatory approvals and are commercialized and generating revenue.
Vycor Medical’s flagship, ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. Vycor Medical is ISO 13485:2003 compliant, has FDA 510(K) clearance for VBAS for brain and spine surgeries and regulatory approvals for brain surgeries in Australia, Canada, China, Europe, Japan, Korea and Russia. For an overview of Vycor Medical’s VBAS see http://player.vimeo.com/video/39766887
NovaVision develops and provides science-driven neurostimulation therapy and other medical technologies that help improve and partially restore sight in patients with neurological vision impairments. The company’s proprietary Visual Restoration Therapy® (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (“TBI”), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the U.S. aimed at the restoration of vision for neurologically induced vision loss and can be prescribed by any ophthalmologist, optometrist, neurologist or physiatrist. VRT also has CE Marking for the EU. NovaVision also recently launched NeuroEyeCoach™, a new Internet-based “direct to the patient” saccadic eye training program. The Company also provides Neuro-Eye Therapy (NeET) in the EU, aimed at increasing visual sensitivity deep within the field defect. For an overview of NovaVision see:
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecast”, “anticipate”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
A CommPro Worldwide PR Event
PR & Media Contact:
Matt Bird, CEO
C: +1 (646) 401-4499